It’s the most wonderful time of the year! All of us here at Medtronic couldn’t be happier to announce the long-anticipated launch of our latest hybrid closed loop system, the MiniMedTM 770G system. As the next step in our innovation pipeline, this system is designed to help support patients ages 2 and up with self-adjusting insulin delivery*, while also providing smartphone connectivity. Specifically, via the MiniMedTM Mobile App, patients can view their glucose trends and insulin delivery on the go while staying connected with their loved ones via the CareLinkTM Connect App. It’s connected care when they need it the most.
Now, we know you must be wondering: “What’s training going to look like for my patients going on the MiniMedTM 770G system in the current COVID-19 environment?”
We want to assure you that as always, patients come first. As a result, back in March our robust team of clinical field experts quickly did what they do best: adapt. Despite complex challenges, they quickly pivoted towards the use of the virtual environment to provide world-class virtual trainings. A recent article published in the Diabetes Technology & Therapeutics journal by Vigersky et.al, showed virtual trainings not only achieved best-in-class satisfaction among patients but also demonstrated short-term glycemic results comparable to in-person training during COVID-19. Additionally, total patient satisfaction levels with virtual trainings on diabetes technology increased by 8% during COVID-19 compared to pre-COVID-19 levels.1
Today, our teams continue to use virtual trainings to make every effort to provide patients with continuity of care and support while adhering to social distancing guidelines. And, while some would consider the technological learning curve a steep one, we’ve learned strategies that make it simple. For example one-on-one trainings, using the video-feature on the virtual platform, using products for live demonstration, and even using closed captioning for those that are hard of hearing. The benefits of virtual learning are also numerous. Not only does it enable us to keep patients and trainers safe, but it also allows for more flexible training schedules while using a platform that is relatively accessible to most patients from wherever they are!
We know virtual trainings are effective and the virtual environment is likely here to stay. With that said, Medtronic looks forward to supporting you and your patients as they begin their journey on the MiniMedTM 770G system.
Refers to SmartGuard™ Auto Mode. Some user interaction required. Individual results may vary.
Vigersky RA, Velado K, Zhong A, Agrawal P, Cordero TL. The Effectiveness of Virtual Training on the MiniMed 670G System in People with Type 1 Diabetes During the COVID-19 Pandemic. Diabetes Technol Ther. 2020 Aug 14. doi: 10.1089/dia.2020.0234. Epub ahead of print. PMID: 32678672.
Important Safety Information: MiniMedTM 770G System with SmartGuardTM Technology
The MiniMed™ 770G system is intended for continuous delivery of basal insulin (at user selectable rates) and administration of insulin boluses (in user selectable amounts) for the management of type 1 diabetes mellitus in persons two years of age and older requiring insulin as well as for the continuous monitoring and trending of glucose levels in the fluid under the skin. The MiniMed™ 770G system includes SmartGuard™ technology, which can be programmed to automatically adjust delivery of basal insulin based on continuous glucose monitoring (CGM) sensor glucose (SG) values and can suspend delivery of insulin when the SG value falls below or is predicted to fall below predefined threshold values.
The Medtronic MiniMed™ 770G system consists of the following devices: MiniMed™ 770G insulin pump, the Guardian™ Link (3) transmitter, the Guardian™ Sensor (3), one-press serter, the Accu-Chek® Guide Link blood glucose meter, and the Accu-Chek® Guide test strips. The system requires a prescription.
The Guardian™ Sensor (3) has not been evaluated and is not intended to be used directly for making therapy adjustments, but rather to provide an indication of when a fingerstick may be required. All therapy adjustments should be based on measurements obtained using a blood glucose meter and not on values provided by the Guardian™ Sensor (3).
All therapy adjustments should be based on measurements obtained using the Accu-Chek® Guide Link blood glucose meter and not on values provided by the Guardian™ Sensor (3). Always check the pump display to ensure the glucose result shown agrees with the glucose results shown on the Accu-Chek® Guide Link blood glucose meter. Do not calibrate your CGM device or calculate a bolus using a blood glucose meter result taken from an alternative site. It is not recommended to calibrate your CGM device when sensor or blood glucose values are changing rapidly, e.g., following a meal or physical exercise.
WARNING: Do not use the MiniMed™ 770G system until appropriate training has been received from a healthcare professional. Training is essential to ensure the safe use of the MiniMed™ 770G system.
Pump therapy is not recommended for people whose vision or hearing does not allow recognition of pump signals and alarms. Pump therapy is not recommended for people who are unwilling or unable to maintain contact with their healthcare professional. The safety of the MiniMed™ 770G system has not been studied in pregnant women. For complete details of the system, including product and important safety information such as indications, contraindications, warnings and precautions associated with system and its components, please consult http://www.medtronicdiabetes.com/important-safety-information#minimed-770g and the appropriate user guide at http://www.medtronicdiabetes.com/download-library